Following a full submission
AWMSG advice |
||
| Status: Recommended | ||
Efavirenz / emtricitabine / tenofovir disoproxil (as fumarate) (Atripla®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infection in adults with virological suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiviral therapy for more than three months and in accordance with current BHIVA guidance. AWMSG is of the opinion that efavirenz / emtricitabine / tenofovir disoproxil (as fumarate) (Atripla®) is not suitable for shared care within NHS Wales. |
||
|
||
Medicine details |
||
| Medicine name | efavirenz / emtricitabine / tenofovir disoproxil (Atripla®) | |
| Formulation | 600 mg / 200 mg / 245 mg film-coated tablet | |
| Reference number | 119 | |
| Indication | Treatment of human immunodeficiency virus-1 (HIV-1) infection in adults with virologic suppression to HIV-1 RNA levels of <50 copies/ml on their current combination antiretroviral therapy for more than three months |
|
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd / Gilead Sciences Ltd | |
| BNF chapter | Infections | |
| Assessment type | Full | |
| Status | Recommended | |
| Advice number | 0209 | |
| NMG meeting date | 27/01/2009 | |
| AWMSG meeting date | 25/02/2009 | |
| Ratification by Welsh Government | 16/03/2009 | |
| Date of issue | 17/03/2009 | |